The Rise and Fall of Patanjali: Lessons from India’s Most Dramatic FMCG Disruption and What the Future Holds
Patanjali Ayurved’s story is nothing short of a modern Indian business saga. Founded in 2006 by yoga guru Baba Ramdev and Acharya Balkrishna, the company exploded onto the scene as a swadeshi challenger to multinational giants in the fast-moving consumer goods (FMCG) sector. It promised affordable, natural, Ayurvedic alternatives and rode a wave of cultural nationalism and wellness trends. At its peak, Patanjali threatened established players like Hindustan Unilever, Colgate, and Dabur. Yet, within years, it faced regulatory scrutiny, consumer trust issues, and revenue pressures in its core business. Today, as of mid-2026, the group shows resilience through restructuring and diversification. This article examines the meteoric rise, the challenges that followed, and the prospects ahead for this iconic Indian brand.
The Foundations and Explosive Growth (2006–2017)
Patanjali Ayurved was established in Haridwar, Uttarakhand, with Acharya Balkrishna holding the majority stake (around 94%) and serving as Managing Director and CEO. Baba Ramdev, already a household name through his yoga programs on television channels like Aastha since the early 2000s, became the public face and strategic driver. The company began with Ayurvedic medicines and wellness products, leveraging modern technology for traditional formulations.
The timing was perfect. India’s consumer market was expanding rapidly, with growing interest in natural and herbal products. Patanjali tapped into several powerful trends: rising nationalism favoring “Made in India” goods, skepticism toward Western multinational corporations, and a broader wellness boom. Products like Dant Kanti toothpaste, herbal soaps, amla juice, chyawanprash, and later instant noodles, biscuits, and ghee were priced aggressively to appeal to price-sensitive middle-class and rural consumers.
Marketing was innovative and deeply personal. Ramdev’s charisma, yoga camps, and direct engagement with followers created a loyal customer base that felt like a movement rather than mere transactions. Distribution expanded aggressively through company-owned outlets, partnerships with retailers like Reliance and Future Group, and a strong rural penetration network.
Financially, the growth was extraordinary. From modest beginnings, revenue surged. By 2014–15, it reached approximately ₹2,000 crore. The following year saw a massive jump to around ₹8,000 crore, followed by a 2016–17 peak of roughly ₹10,000–10,500 crore. Analysts from CLSA and HSBC hailed it as one of India’s fastest-growing FMCG companies. Patanjali’s success reportedly impacted at least 13 listed competitors, prompting them to bolster their own herbal offerings.
By this point, the company had built manufacturing facilities like the Patanjali Food and Herbal Park in Haridwar with massive capacity. It diversified into personal care, foods, household items, and even ventured into areas like clothing (Patanjali Paridhan) and telecom partnerships. The brand symbolized empowerment through tradition, resonating deeply in a market hungry for authentic Indian alternatives.
Signs of Strain and the Onset of Decline (2017 Onwards)
The peak around 2016–17 marked the beginning of challenges. Revenue reportedly dipped to about ₹9,500 crore in 2017–18 and continued facing headwinds. Several factors converged to slow the momentum.
The implementation of Goods and Services Tax (GST) in 2017 disrupted supply chains, pricing strategies, and input credit mechanisms, particularly affecting a company that had scaled rapidly on a somewhat informal or fast-growth model. Operational complexities arose from managing hundreds of products across diverse categories without the depth of professional management typical in multinational firms.
More damaging were the regulatory and legal controversies. Patanjali faced multiple notices from FSSAI and the AYUSH Ministry regarding product quality, labeling, and advertising claims. The COVID-19 period intensified scrutiny. In 2020, the launch of Coronil as an immunity booster (with initial stronger claims) drew criticism, state-level bans in some cases, and legal challenges. Public statements by Ramdev criticizing allopathy further polarized opinions and invited backlash from the medical community, including the Indian Medical Association (IMA).
A major flashpoint was misleading advertisements. Claims suggesting cures for serious conditions like diabetes, heart disease, liver problems, and infertility violated provisions of the Drugs and Magic Remedies (Objectionable Advertisements) Act. The IMA filed petitions, leading to Supreme Court intervention in 2023–2024. The Court issued strong observations, ordered public apologies in newspapers, and saw Uttarakhand authorities suspend licenses for certain products. While some cases saw relief in 2025, the episodes significantly dented consumer trust, especially in urban and semi-urban segments.
Consumer perception shifted for some towards skepticism about exaggerated claims and occasional quality concerns. Intense competition from incumbents, who improved their herbal portfolios and marketing, added pressure. Core operations revenue for Patanjali Ayurved declined. In FY24, revenue from operations fell 14% to ₹6,460 crore (partly due to deliberate restructuring), though total income rose to ₹9,335 crore aided by other income sources, including transactions related to group entities. Profits saw a significant boost from these factors, and advertising spends increased sharply to rebuild visibility.
To streamline, the company transferred its food business (biscuits, ghee, cereals, nutraceuticals) to Patanjali Foods Ltd in 2022 and later the home and personal care segment. This shifted focus for the core Ayurved entity toward medicines and select wellness products while leveraging the listed entity for scale.
Current Landscape and Group Performance (2025–2026)
As of 2026, the Patanjali story is bifurcated. The core Ayurved business continues navigating compliance requirements and trust rebuilding, with increased marketing efforts evident. However, the broader group demonstrates strength. Patanjali Foods Ltd, the listed arm (which includes the acquired Ruchi Soya edible oils business), has performed robustly. It crossed ₹40,000 crore in revenue for FY26, with approximately 18% year-on-year growth, improved profits (up around 40% in some reports), and strong momentum in FMCG segments like home and personal care (reportedly +35% growth in periods). Edible oils remain a cornerstone, with recovery and expansion in value-added categories.
Group-level turnover hovers in the ₹40,000–45,000 crore range according to various reports. Diversification is accelerating: a new Patanjali Emergency & Critical Care Hospital was inaugurated in January 2026, a mega food park project in Andhra Pradesh, insurance acquisitions, and international wellness partnerships (e.g., with Russia). Baba Ramdev has articulated ambitious goals, including pushing the group toward ₹1 lakh crore turnover by 2028.
Prospects and Lessons for the Future
Patanjali’s future hinges on balancing its heritage strengths with necessary evolution. The Ayurveda and wellness sector enjoys strong tailwinds in India, supported by government initiatives for AYUSH, rising health consciousness, and export potential. Patanjali retains formidable assets: deep brand recall, extensive distribution (especially rural), and a loyal customer base that values its swadeshi ethos.
For the core Ayurved business, success depends on strict adherence to advertising regulations—focusing on wellness benefits rather than unsubstantiated cure claims—consistent quality, and transparent communication. Rebuilding urban trust while maintaining rural dominance will be key. The surge in promotional spending indicates proactive efforts, but long-term credibility requires evidence-based approaches where possible.
The Patanjali Foods vertical offers a blueprint for scaled, professional growth. With experienced leadership like CEO Sanjeev Asthana, it demonstrates how leveraging distribution networks, category expansion, and operational efficiencies can deliver sustainable results in competitive segments like edible oils and FMCG. Analysts project steady single-digit to low double-digit growth potential, contingent on market conditions, rural demand, and commodity prices.
At the group level, diversification into healthcare, insurance, and food processing reduces reliance on any single category. However, execution risks remain high for new ventures. Macro factors such as inflation, consumer spending, and regulatory environment will influence outcomes. The founder’s high public profile continues to be a double-edged sword—powerful for inspiration but potentially polarizing.
In conclusion, Patanjali’s rise exemplified the power of cultural resonance, entrepreneurial agility, and market timing in disrupting a massive industry. Its challenges highlighted the pitfalls of rapid scaling without robust compliance and governance frameworks, particularly in a regulated sector like health and wellness. The “fall” was less a collapse than a painful maturation process.
Patanjali is unlikely to fade away. Instead, it may transform into a more diversified, professionally managed conglomerate while preserving its Ayurvedic soul. If it successfully prioritizes trust, innovation, and regulatory harmony, the group can capitalize on India’s growing wellness economy. The coming years will test whether Patanjali can evolve from a disruptive force into a durable institution. For Indian entrepreneurship, its trajectory offers enduring lessons: vision and speed win markets, but sustainability demands discipline and adaptability.
About The Author
